DOCSLIB.ORG

Nasdaq Capital Market Friday, December 28, 2018 5:32 PM

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Nasdaq Capital Market Friday, December 28, 2018 5:32 PM Name Symbol Close 3PEA International TPNL 3.35 Abeona Therapeutics ABEO 7.02 Ability ABIL 2.02 Abraxas Petroleum AXAS 1.08 Acasti Pharma ACST 0.73 Accelerate Diagnostics AXDX 11.78 Acer Therapeutics ACER 18.25 Achieve Life Sciences ACHV 1.2 ACNB ACNB 38.73 Adamis Pharmaceuticals ADMP 2.1 Adesto Technologies IOTS 4.3 ADial Pharmaceuticals ADIL 5.55 ADMA Biologics ADMA 2.23 ADOMANI ADOM 0.25 Aehr Test Systems AEHR 1.44 Aerpio Pharmaceuticals ARPO 1.71 AEterna Zentaris AEZS 2.97 Aethlon Medical AEMD 1.52 Agenus AGEN 2.39 AGM Group Holdings AGMH 28.05 Airgain AIRG 10.04 AirMedia Group ADR AMCN 0.24 Air T AIRT 24.03 Akari Therapeutics ADR AKTX 1.63 Akers Biosciences AKER 1.27 Akoustis Technologies AKTS 4.79 Alberton Acquisition Cl A ALAC 9.8 Alberton Acquisition WT ALACW 0.12 Albireo Pharma ALBO 23.18 Aldeyra Therapeutics ALDX 8 Alithya Group Cl A ALYA 2.55 Alkaline Water WTER 3.24 Allegro Merger Rt ALGRR 0.3 Alliance MMA AMMA 0.17 Allied Healthcare Products AHPI 1.89 Alliqua BioMedical ALQA 2 Alta Mesa Resources AMR 1 Alta Mesa Resources WT AMRWW 0.08 Altus Midstream ALTM 7.75 AMCI Acquisition AMCIU 9.95 American Electric Technologies AETI 0.89 Ameri Holdings AMRH 0.17 Ameri Holdings WT AMRHW 0.03 Ames National ATLO 25.72 Anavex Life Sciences AVXL 1.52 Anixa Biosciences ANIX 4 Antares Pharma ATRS 2.63 Apollo Medical Holdings AMEH 20.73 Appliance Recycling Centers of ARCI 0.5 America Applied DNA Sciences APDN 0.38 Applied DNA Sciences WT APDNW ... Apricus Biosciences APRI 0.2 Aptose Biosciences APTO 1.91 AquaBounty Technologies AQB 1.68 Aqua Metals AQMS 1.8 Aradigm ARDM 0.34 ARCA biopharma ABIO 0.31 Arcadia Biosciences RKDA 3.01 ARC Group Worldwide ARCW 1.04 Arcimoto FUV 2.39 Aridis Pharmaceuticals ARDS 10.3 Art's Way Manufacturing ARTW 1.94 ARYA Sciences Acquisiton ARYAU 10.33 Aspen Group ASPU 5.47 Assembly Biosciences ASMB 22.12 Astrotech ASTC 5.29 Asure Software ASUR 5.13 ASV Holdings ASV 2.11 Athersys ATHX 1.42 Atomera ATOM 2.65 Atossa Genetics ATOS 0.99 Attis Industries ATIS 0.18 Attunity ATTU 18.99 AudioEye AEYE 8.46 Auris Medical Holding EARS 0.49 AutoWeb AUTO 3.21 Avenue Therapeutics ATXI 5.4 Avid Bioservices CDMO 4.09 Avinger AVGR 0.2 AxoGen AXGN 19.37 Aytu BioScience AYTU 0.78 AzurRx BioPharma AZRX 1.3 Bank First National BFC 48.21 Bank of Marin Bancorp BMRC 40.73 Bank of South Carolina BKSC 18.09 Bank of the James Financial Group BOTJ 13.1 Benitec Biopharma ADR BNTC 1.51 BeyondSpring BYSI 19.61 Big Rock Partners Acquisition Rt BRPAR 0.3 Bioanalytical Systems BASI 1.28 Bioblast Pharma ORPN 0.85 Biocept BIOC 0.82 BioDelivery Sciences International BDSI 3.29 Biofrontera ADR BFRA 11.49 BioHiTech Global BHTG 1.94 BIO-key International BKYI 0.87 Biolase BIOL 1.03 BioLife Solutions BLFS 12.18 BioLine RX ADR BLRX 0.43 Biomerica BMRA 1.79 Bionano Genomics BNGO 4.9 BiondVax Pharmaceuticals ADR BVXV 4.4 Bio-Path Holdings BPTH 0.18 Biosig Technologies BSGM 4.17 BioXcel Therapeutics BTAI 3.94 Bison Capital Acquisition BCAC 10.37 Bison Capital Acquisition Rt BCACR 0.3 Bison Capital Acquisition WT BCACW 0.24 Black Ridge Acquisition BRAC 10.05 Black Ridge Acquisition Rt BRACR 0.3 Black Ridge Acquisition WT BRACW 0.34 Blink Charging BLNK 1.77 Blink Charging WT BLNKW 0.22 Bonso Electronics International BNSO 1.84 Borqs Technologies BRQS 3.2 B.O.S. Better Online Solutions BOSC 2.2 Boston Omaha BOMN 23.69 Boxlight Cl A BOXL 1.26 Brainstorm Cell Therapeutics BCLI 3.37 Bridgeline Digital BLIN 0.29 Bridgewater Bancshares BWB 10.22 Broadvision BVSN 1.06 Broadway Financial BYFC 1.09 Broadwind Energy BWEN 1.2 BSB Bancorp BLMT 27.78 Caladrius Biosciences CLBS 3.54 Cambridge Bancorp CATC 83.27 Cancer Genetics CGIX 0.27 Capricor Therapeutics CAPR 0.37 Capstone Turbine CPST 0.6 Carolina Financial CARO 29.71 Carolina Trust BancShares CART 7.57 Carver Bancorp CARV 3.44 CASI Pharmaceuticals CASI 4.4 CAS Medical Systems CASM 1.64 Catalyst Biosciences CBIO 8 Catalyst Pharmaceuticals CPRX 1.98 Catasys CATS 9.55 CBM Bancorp CBMB 12.55 Celcuity CELC 23.69 Celldex Therapeutics CLDX 0.2 Cellectar Biosciences CLRB 1.52 Cellectar Biosciences WT Series A CLRBZ 0.04 Cellect Biotechnology ADR APOP 2.36 Celsion CLSN 1.44 Celsius Holdings CELH 3.45 Cemtrex CETX 0.6 Centennial Resource Development CDEV 10.84 Central Federal CFBK 12 Central Valley Community Bancorp CVCY 18.49 Centric Brands CTRC 3.37 Century Casinos CNTY 7.13 Cerecor CERC 3.14 Cesca Therapeutics KOOL 0.28 Champions Oncology CSBR 8.39 Chanticleer Holdings BURG 1.3 Charles&Colvard CTHR 0.87 ChaSerg Technology Acquisition CTACU 9.98 ChaSerg Technology Acquisition Cl A CTAC 9.68 Check-Cap CHEK 2.1 Check-Cap WT CHEKW 0.12 Check-Cap WT Series C CHEKZ 0.35 Checkpoint Therapeutics CKPT 1.82 Chembio Diagnostics CEMI 5.4 Cherokee CHKE 0.57 CHF Solutions CHFS 0.53 China Advanced Construction CADC 2 Materials Group China Automotive Systems CAAS 2.39 China Ceramics CCCL 0.8 China Commercial Credit GLG 0.32 China Customer Relations Centers CCRC 13.31 China HGS Real Estate HGSH 0.9 China Jo-Jo Drugstores CJJD 2 China Lending CLDC 0.94 China Natural Resources CHNR 1.62 ChinaNet Online Holdings CNET 1.27 China Recycling Energy CREG 0.67 ChromaDex CDXC 3.4 Citius Pharmaceuticals CTXR 1 Citizens&Northern CZNC 25.48 Civista Bancshares CIVB 16.83 ClearOne CLRO 1.2 ClearSign Combustion CLIR 1.07 ClearSign Combustion WT CLIRW 0.01 Cleveland BioLabs CBLI 1.08 CM Seven Star Acquisition CMSS 10.11 CM Seven Star Acquisition Rt CMSSR 0.4 CM Seven Star Acquisition WT CMSSW 0.29 Cocrystal Pharma COCP 3.3 Coda Octopus Group CODA 5.67 Co-Diagnostics CODX 1.25 Coffee Holding JVA 3.7 Cohbar CWBR 3.37 Collplant Holdings ADR CLGN 3.92 Command Center CCNI 3.77 Community Bankers Trust ESXB 7.3 Community Financial TCFC 29.18 Community First Bancshares CFBI 10.99 Comstock Holding Cl A CHCI 1.7 Concrete Pumping Holdings BBCP 8.04 Concrete Pumping Holdings WT BBCPW 0.75 Constellation Alpha Capital Rt CNACR 0.19 Constellation Alpha Capital WT CNACW 0.15 ContraFect CFRX 1.44 ContraVir Pharmaceuticals CTRV 0.29 Cool Holdings AWSM 2.02 Corbus Pharmaceuticals Holdings CRBP 5.88 Corcept Therapeutics CORT 13.02 Correvio Pharma CORV 2.29 CounterPath CPAH 1.29 CPI Card Group PMTS 2.25 CPS Technologies CPSH 1.05 Creative Realities CREX 2.14 Creative Realities WT CREXW 0.4 Crown Crafts CRWS 5.47 CryoPort CYRX 9.7 CryoPort WT CYRXW 7.5 CTI BioPharma CTIC 0.8 CTI Industries CTIB 3 Cue Biopharma CUE 4.64 CUI Global CUI 1.23 CVD Equipment CVV 3.7 Cyanotech CYAN 3.08 Cyclacel Pharmaceuticals CYCC 0.61 CYREN CYRN 2.79 Cytori Therapeutics CYTX 0.3 Cytori Therapeutics WT CYTXZ ... Cytosorbents CTSO 7.82 CytRx CYTR 0.42 Daily Journal DJCO 234.4 Dare Bioscience DARE 0.67 DarioHealth DRIO 0.74 DASAN Zhone Solutions DZSI 13.92 Daseke DSKE 3.67 Daseke WT DSKEW 0.18 Data I/O DAIO 5.22 Datasea DTSS 4.1 DD3 Acquisition DDMXU 10 DelMar Pharmaceuticals DMPI 0.37 Del Taco Restaurants TACO 10.02 Del Taco Restaurants WT TACOW 1.12 Delta Technology Holdings DELT 0.95 Denny's DENN 16.26 Diamedica Therapeutics DMAC 2.86 Diffusion Pharmaceuticals DFFN 2.25 Digital Ally DGLY 2.83 Digital Turbine APPS 1.85 Diversicare Healthcare Services DVCR 2.26 Diversified Restaurant Holdings SAUC 0.99 DLH Holdings DLHC 4.37 DNB Financial DNBF 26.96 Dolphin Entertainment DLPN 0.75 Dragon Victory International LYL 1.48 DropCar DCAR 0.24 DryShips DRYS 5.5 Dynasil of America DYSL 0.87 Dynatronics DYNT 2.79 Dynavax Technologies DVAX 8.63 Eagle Bancorp EGBN 49 Eagle Financial Bancorp EFBI 15.28 Eastside Distilling EAST 6.1 Eco-Stim Energy Solutions ESES 0.08 Edison Nation EDNT 4.93 eGain EGAN 6.65 Ekso Bionics Holdings EKSO 1.31 Electrameccanica Vehicles SOLO 1.06 Electro-Sensors ELSE 3.4 Elmira Savings Bank ESBK 18.85 Eltek ELTK 2.48 Emclaire Financial EMCF 30.8 ENDRA Life Sciences NDRA 1.78 ENDRA Life Sciences WT NDRAW 0.6 Energous WATT 5.87 Energy Focus EFOI 0.57 ENGlobal ENG 0.68 Enochian Biosciences ENOB 6.93 Entera Bio ENTX 3.28 Esquire Financial Holdings ESQ 21.51 Essa Pharma EPIX 2.11 Establishment Labs Holdings ESTA 25.85 EuroDry EDRY 8.75 Euroseas ESEA 0.65 Euro Tech Holdings CLWT 2.33 Evofem Biosciences EVFM 4.06 Evoke Pharma EVOK 2.3 Evolving Systems EVOL 1.15 EXACT Sciences EXAS 61.19 Exela Technologies XELA 3.74 Eyegate Pharmaceuticals EYEG 0.48 Eyegate Pharmaceuticals WT EYEGW 0.04 Eyenovia EYEN 2.6 Falcon Minerals FLMN 8.2 Falcon Minerals WT FLMNW 0.64 Farmers&Merchants Bancorp FMAO 38.08 Farmers National Banc FMNB 12.52 Farmmi FAMI 3.95 FAT Brands FAT 4.91 Fauquier Bankshares FBSS 18.31 Federal Life Group FLF 11.29 Federal Street Acquisition Un FSACU 10 Fennec Pharmaceuticals FENC 6.2 FFBW FFBW 10 Fibrocell Science FCSC 1.5 Finjan Holdings FNJN 2.49 FinTech Acquisition III FTACU 9.96 First Capital FCAP 41 First Choice Bancorp FCBP 22.35 First Community (South Carolina) FCCO 19.42 First of Long Island FLIC 19.81 First Savings Financial Group FSFG 51.45 First US Bancshares FUSB 7.83 Five Star Senior Living FVE 0.49 FlexShopper FPAY 0.72 FlexShopper WT FPAYW 0.18 FNCB Bancorp FNCB 8.6 Fonar FONR 20.42 Foresight Autonomous Holdings FRSX 1.65 ADR Fortress Biotech FBIO 0.89 Forum Merger II Cl A FMCI 9.65 Forum Merger II Un FMCIU 10.12 Forum Merger II WT FMCIW 0.45 Forward Industries FORD 1.28 FS Bancorp FSBW 42.24 FSB Bancorp FSBC 17 Fuling Global FORK 3.85 Full House Resorts FLL 2.11 Fusion Connect FSNN 1.67 Fuwei Films Holdings FFHL 2.08 FVCBankcorp FVCB 16.69 Galectin Therapeutics GALT 3.77 Galmed Pharmaceuticals GLMD 7.26 Genetic Technologies ADR GENE 0.58 Genius Brands International GNUS 2.05 Genocea Biosciences GNCA 0.31 Genprex GNPX 1.14 Gevo GEVO 2.07 GigaMedia GIGM 3.05 Global Eagle Entertainment ENT 2.13 Globus Maritime GLBS 3.02 Golden Bull DNJR 5.5 Good Times Restaurants GTIM 2.38 Gordon Pointe Acquisition Un GPAQU 10.34 Gores Holdings III Cl A GRSH 9.72 Green Brick Partners GRBK 7.11 Greene County Bancorp GCBC 31.26 Greenpro Capital GRNQ 4.31 Grupo Financiero Galicia ADR GGAL 26.92 GSE Systems GVP 2.17 GTx GTXI 0.78 GTY Technology Holdings Cl A GTYH 10.05 GTY Technology Holdings WT GTYHW 0.74 GWG Holdings GWGH 9.24 G.
Recommended publications
  • Embedded Linux Systems with the Yocto Project™

    Embedded Linux Systems with the Yocto Project™

    OPEN SOURCE SOFTWARE DEVELOPMENT SERIES Embedded Linux Systems with the Yocto Project" FREE SAMPLE CHAPTER SHARE WITH OTHERS �f, � � � � Embedded Linux Systems with the Yocto ProjectTM This page intentionally left blank Embedded Linux Systems with the Yocto ProjectTM Rudolf J. Streif Boston • Columbus • Indianapolis • New York • San Francisco • Amsterdam • Cape Town Dubai • London • Madrid • Milan • Munich • Paris • Montreal • Toronto • Delhi • Mexico City São Paulo • Sidney • Hong Kong • Seoul • Singapore • Taipei • Tokyo Many of the designations used by manufacturers and sellers to distinguish their products are claimed as trademarks. Where those designations appear in this book, and the publisher was aware of a trademark claim, the designations have been printed with initial capital letters or in all capitals. The author and publisher have taken care in the preparation of this book, but make no expressed or implied warranty of any kind and assume no responsibility for errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of the use of the information or programs contained herein. For information about buying this title in bulk quantities, or for special sales opportunities (which may include electronic versions; custom cover designs; and content particular to your business, training goals, marketing focus, or branding interests), please contact our corporate sales depart- ment at [email protected] or (800) 382-3419. For government sales inquiries, please contact [email protected]. For questions about sales outside the U.S., please contact [email protected]. Visit us on the Web: informit.com Cataloging-in-Publication Data is on file with the Library of Congress.
  • Notice of 2020 Annual Meeting of Shareholders

    Notice of 2020 Annual Meeting of Shareholders

    10 Ha-Menofim St., 5th Floor Herzliya, Israel 4672561 NOTICE OF 2020 ANNUAL MEETING OF SHAREHOLDERS June 25, 2020 NOTICE IS HEREBY GIVEN that the Annual Meeting of Shareholders (the “Annual Meeting”) of Cyren Ltd., a company formed under the laws of the State of Israel, will be held on July 30, 2020 at 11:00 a.m. Eastern Time, at the offices of our subsidiary, Cyren Inc., located at 1430 Spring Hill Road, Suite 330, McLean, VA 22102, for the following purposes: 1. to elect nine directors, as described in the accompanying proxy statement, to serve until the next annual meeting of shareholders or until their successors are elected; 2. to approve the compensation to our Chairman of the Board; 3. to approve the equity-based compensation to our Chief Executive Officer; 4. to approve, as required by Nasdaq Listing Rule 5635(d), the issuance of more than 19.99% of our outstanding ordinary shares in connection with our 5.75% Convertible Debentures due 2024; 5. to ratify and approve the re-appointment of Kost, Forer, Gabbay & Kasierer (a member firm of Ernst & Young Global) as our independent registered public accountants for the year ending December 31, 2020 and for the year commencing January 1, 2021 and until the next annual meeting of shareholders and to authorize our Board of Directors and Audit Committee to determine its fees; 6. to approve, on an advisory basis, the compensation of our named executive officers; 7. to review and discuss our consolidated financial statements for the fiscal year ended December 31, 2019; and 8.
  • Market Cap Close ADV 1598 67Th Pctl 745,214,477.91 $ 23.96

    Market Cap Close ADV 1598 67Th Pctl 745,214,477.91 $ 23.96

    Market Cap Close ADV 1598 67th Pctl $ 745,214,477.91 $ 23.96 225,966.94 801 33rd Pctl $ 199,581,478.89 $ 10.09 53,054.83 2399 Ticker_ Listing_ Effective_ Revised Symbol Security_Name Exchange Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M AAMC Altisource Asset Management Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L AEL American Equity Inv Life Hldg Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L AHL ASPEN Insurance Holding Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
  • Advancing Cell Therapeutic Products for Clinical Use

    Advancing Cell Therapeutic Products for Clinical Use

    Advancing cell therapeutic products for clinical use 1 Proprietary data of Pluristem Therapeutics Inc. Forward Looking Statement This presentation concerning Pluristem Therapeutics may include forward- looking statements which represent Pluristem Therapeutics' expectations or beliefs regarding future events. I caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in Pluristem Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. Pluristem Therapeutics assumes no obligation to update these forward- looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements. www.pluristem.com 2 Proprietary data of Pluristem Therapeutics Inc. Corporate Overview • Cell therapy company (NasdaqCM: PSTI, TASE: PSTI) • Using off-the-shelf, placenta-derived cells to achieve both local and systemic therapeutic effects – no tissue matching needed • First-in-class 3D cell culturing technology allowing for efficient, controlled production of multiple cell products in commercial quantities – “the process is the product” • Active with regulators in the U.S., EU, S. Korea, Australia & Israel • Demonstrated safety and efficacy in 3 clinical studies (two Phase I and one Phase I/II study) 3 Proprietary data of Pluristem Therapeutics Inc. Financial Overview • Market Cap: ~ $200 million • Cash and marketable securities: $41 million (March, 2015) • No debt • Net burn: ~ $23 million • 165 employees (16 PhD, 4 MD) • IP Ownership: over 40 granted patents and ~150 pending applications 4 Proprietary data of Pluristem Therapeutics Inc.
  • E-Waste Generation from Mobile Phones and Sustainability Issues for Designers

    E-Waste Generation from Mobile Phones and Sustainability Issues for Designers

    RPS Research into Design — Supporting Sustainable Product Development “icord2011-lineup” 2010/12/24 523 E-WASTE GENERATION FROM MOBILE PHONES AND SUSTAINABILITY ISSUES FOR DESIGNERS Pradeep G. Yammiyavara and Vikash Kumarb 1Department of Design, IIT Guwahati, Assam, India. Email: [email protected], [email protected] Recent contribution of mobile phones as e-waste generators is a matter of concern due to the product’s shorter lifespan, large disposal volume, toxic nature of materials, higher energy requirement at production stage etc. With the predicted exponential penetration of mobile phones in countries such as India and China e-waste is likely to nullify the benefits unless properly approached. Addressing these concerns the first part of this paper attempts to estimate the volume of e-waste generated by mobile phones. Identification of key issues impacting the sustainability of mobile phones is discussed in the second part using product samples. This paper is an attempt to understand issues involved in sustainable design and explore possible methods of addressing sustainability at the designing stage of a product. Keywords: E-waste, Mobile phones, Design for sustainability, Culture. 1. INTRODUCTION Common understanding of the term e-waste, or electronic waste, is old, end-of-life electronic appliances such as computers, laptops, TVs, DVD players, mobile phones, mp3 players etc; which have been disposed of by their original users. Technically, electronic waste is only a subset of WEEE (Waste Electrical and Electronic Equipment) as defined by OECD (Organization for Economic Co- operation and Development) as any appliance that uses an electric power supply and has reached its end-of-life [1].
  • Node Layout of Recycling Network for Cell Phones in China Under the Third Party Logistics

    Node Layout of Recycling Network for Cell Phones in China Under the Third Party Logistics

    International Journal of u- and e- Service, Science and Technology Vol.8, No. 9 (2015), pp.1-12 http://dx.doi.org/10.14257/ijunesst.2015.8.9.01 Node Layout of Recycling Network for Cell Phones in China under the Third Party Logistics Danning Li1, Xianliang Shi1 and Chunhua Shi2 1School of Economics and Management, Beijing Jiaotong University, Beijing, China, 100044 2Higher Education Press, Beijing, China, 100029 [email protected]; [email protected]; [email protected] Abstract With the increasing acceleration of updating rate for mobile phones in China, the processing procedure of cell phones has aroused a problem for the whole society. Meantime, environmental pollution and waste of resources result from improper processing approaches of such products. In this paper, the processing modes and corresponding reverse logistics network are analyzed scientifically and completely in terms of recycling by the third party reverse logistics enterprises. Then, a mathematical programming model is proposed in the case of multi-varieties phones and stochastic circumstances to handle the problem of node arrangement and facility location, which taking both cost objective and environment objective into consideration. To combat the model, we design a hybrid intelligent algorithm consisting of genetic algorithm, stochastic simulation and linear programming. Finally a numerical example validates the feasibility of the model and sensitivity analysis is conducted to illustrate its reliability. Such method can be treated as a practice guideline and some suggestions regarding the layout construction are put forward in the end. Keywords: The third party reverses logistics, node layout, stochastic circumstances, multi-objective programming, hybrid intelligent algorithm 1.
  • Market Cap Close ADV

    Market Cap Close ADV

    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
  • Biolinerx Ltd. (Translation of Registrant’S Name Into English) ______

    Biolinerx Ltd. (Translation of Registrant’S Name Into English) ______

    SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 _______________________ BioLineRx Ltd. (Translation of registrant’s name into English) _______________________ 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) _______________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☑ Form 40-F ☐ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: Yes ☐ No ☑ The registrant hereby announces that it has entered into an employment agreement with Hillit Mannor Shachar, M.D., MBA, M.S.F.S., to serve as its new Vice President Business Development, effective April 1, 2018. Dr. Shachar will be responsible for BioLineRx’s business development, commercialization of assets and pipeline strategy. Dr. Shachar joins BioLineRx with over 15 years of experience in senior business development, corporate development and venture capital positions in the life sciences field. Her recent experience has included service as Vice President Business Development of Pluristem Therapeutics (NASDAQ:PSTI), a leading developer of placenta-based cell therapy products, and Director of New Business Development at West Pharmacuetical Services. In addition, Dr. Shachar has served at several life science companies and venture capital funds, including Apax Partners, Nektar Therapeutics, Orex Computed Radiography, Kodak and Transpharma Medical.
  • Submission Data File

    Submission Data File

    Date: 05/27/2016 04:48 PM Vintage Project: v441042 Form Type: 6-K Client: v441042_Pointer Telocation Ltd_6-K Submission Data File General Information Form Type* 6-K Contact Name Chico Kim Contact Phone 866-683-5252 Filer File Number Filer CIK* 0000920532 [Pointer Telocation Ltd] (Pointer Telocation Ltd) Filer CCC* ********** Confirming Copy No Notify via Website only No Return Copy No SROS* NASD Period* 05-27-2016 (End General Information) Document Information File Count* 32 Document Name 1* v441042_6k.htm Document Type 1* 6-K Document Description 1 6-K Document Name 2* v441042_ex99-1.htm Document Type 2* EX-99.1 Document Description 2 Exhibit 99.1 Document Name 3* v441042_ex99-2.htm Document Type 3* EX-99.2 Document Description 3 Exhibit 99.2 (End Document Information) Notifications Notify via Website only No E-mail 1 [email protected] (End Notifications) Date: 05/27/2016 04:48 PM Vintage Project: v441042 Form Type: 6-K Client: v441042_Pointer Telocation Ltd_6-K File: v441042_6k.htm Type: 6-K Pg: 1 of 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2016 Commission File Number: 001-13138 Pointer Telocation Ltd. (Translation of registrant's name into English) 14 Hamelacha Street, Rosh Ha'ayin, Israel 4809133 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
  • PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant As Specified in Its Charter)

    PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 98-0351734 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) MATAM Advanced Technology Park, Building No. 5, Haifa, Israel 31905 (Address of principal executive offices) (Zip Code) Registrant's telephone number 011-972-74-7107259 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, par value $0.00001 Nasdaq Capital Market Securities registered pursuant to Section 12(g) of the Act: None. (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  • 2018 Annual Report TAT Technologies

    2018 Annual Report TAT Technologies

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _____________ ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report ……………….. Commission file number: 0-16050 TAT TECHNOLOGIES LTD. (Exact name of Registrant as specified in its charter and translation of Registrant’s name into English) Israel (Jurisdiction of incorporation or organization) P.O. Box 80, Gedera 7075002, Israel (Address of principal executive offices) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Ordinary Shares, NIS 0.90 Par Value NASDAQ Global Market Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer’s classes of capital or Common stock as of the close of the period covered by the annual report: Ordinary Shares, par value NIS 0.90 per share…………… 8,874,696 (as of December 31, 2018) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
  • The True Environmental Impact of Smartphones?

    The True Environmental Impact of Smartphones?

    Int J Life Cycle Assess (2015) 20:1181–1196 DOI 10.1007/s11367-015-0909-4 UNCERTAINTIES IN LCA Redefining scope: the true environmental impact of smartphones? James Suckling1 & Jacquetta Lee1 Received: 3 September 2014 /Accepted: 19 May 2015 /Published online: 10 June 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract impact from 8.5 to 18.0 kg CO2-eq, other phases are less Purpose The aim of this study is to explore the literature sur- affected. Addition of the network increases the use phase by rounding the environmental impact of mobile phones and the another 24.7 kg CO2-eq. In addition, it is shown that take-back implications of moving from the current business model of of mobile phones is not effective at present and that prompt selling, using and discarding phones to a product service sys- return of the phones could result in reduction in impact by best tem based upon a cloud service. The exploration of the im- reuse potential and further reduction in toxic emissions pacts relating to this shift and subsequent change in scope is through inappropriate disposal. explored in relation to the life cycle profile of a typical Conclusions The way in which consumers interact with their smartphone. phones is changing, leading to a system which is far more Methods A literature study is conducted into the existing lit- integrated with the internet. A product service system based erature in order to define the characteristics of a Btypical^ upon a cloud service highlights the need for improved energy smartphone.